Redeye comments on Faron’s decision to trigger the second €10m tranche of the Heights Capital Management convertible bond. This move was expected following the positive phase II readout from the BEXMAB study. We view the financing as a necessary step to secure operational continuity ahead of the upcoming registrational trials with bexmarilimab.
LÄS MER
